Introduction {#Sec1}
============

Clinical practice guidelines (CPGs) are "statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options." \[[@CR1]\]. CPGs are a representative tool for standardizing medical interventions and improve healthcare quality. In Japan, CPG development, using evidence-based medicine (EBM), began in the late 1990s with government support. Currently, 30--40 CPGs are developed per year, mainly by academic societies.

With the spread of CPGs in Japan, infrastructure to promote their use is also being developed. This includes clearing houses and standard manuals for developing CPGs. The Toho University Medical Media Center and the Medical Information Network Distribution Service Guideline Center of the Japan Council for Quality Health Care both operate CPG clearing houses \[[@CR2], [@CR3]\].

The Appraisal of Guidelines for Research and Evaluation (AGREE) instrument, developed by the AGREE Enterprise, is a quantitative method for evaluating CPGs. The AGREE instrument determines items that must be satisfied by CPGs, and is expected to facilitate cost effective CPG development and improve CPG quality \[[@CR4]\]. In 2010, the original version (AGREE I) was revised and published as AGREE II \[[@CR5]--[@CR7]\]. Several studies evaluated CPGs using the AGREE I or AGREE II \[[@CR8]--[@CR10]\]. However, the continuity of the data obtained from AGREE I and AGREE II has not yet been demonstrated. The AGREE I was widely used and there is large amount of associated data; investigation of the continuity and conversion of data between AGREE I and II is necessary to make full use of AGREE I data.

We investigated the continuity of AGREE I and AGREE II data, and the conversion method from AGREE I data to AGREE II data.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

A team consisting of three experienced librarians evaluated 68 CPGs, based on EBM issued in 2011--2012 using the AGREE I \[[@CR11]\] and AGREE II \[[@CR12]\]. The evaluated CPGs were all issued in 2011--2012 in Japan. Their contents were checked and judged by expert librarians as to whether they were prepared using EBM methodology, or not. The librarians who evaluated the CPGs have knowledge about the CPG preparation and experience using the AGREE tool. The librarians conducted independent evaluations and did not adjust the result; the results were aggregated into standardized scores. Correlation coefficients were calculated for the domains and items of the two instruments.

AGREE I comprised one overall assessment item and six domains: (1) scope and purpose; (2) stakeholder involvement; (3) rigor of development; (4) clarity of presentation; (5) applicability; (6) editorial independence, totaling 23 items. Each item is rated on a 4-point Likert scale (1 = "Strongly Disagree" to 4 = "Strongly Agree"). A standardized score for each domain was calculated according the formula shown below:$$\documentclass[12pt]{minimal}
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For example, the scope and purpose domain consists of three items; the sum of the maximum possible score is 3 × 3 × 3 = 27, and the sum of the minimum possible score is 1 × 3 × 3 = 9 \[[@CR11]\].

AGREE II is based on AGREE I, incorporating four distinct changes. First, the rating scale was changed from a 4-point to a 7-point Likert scale (1 = "Strongly Disagree" to 7 = "Strongly Agree"). Second, an item was added as a second overall guideline assessment item: "Rate the overall quality of this guideline". Third, the wording or expression of several items was changed, although the meaning of the items was preserved. Finally, Q7 (AGREE I) "The guideline has been piloted among end users" was removed, and was incorporated in Q19 (AGREE II) "The guideline describes facilitators and barriers to its application" and a new item Q9 (AGREE II) "The strengths and limitations of the body of evidence are clearly described". Therefore, Q7 (AGREE I) and Q9 (AGREE II) were excluded from analysis in the present study. A comparison of AGREE I and AGREE II items is shown in Table [1](#Tab1){ref-type="table"}.Table 1Comparison between the AGREE I and AGREE IIAGREE IAGREE IIChange from AGREE I to AGREE IIDomainNoItemItemNoDomain1. Scope and purpose1The overall objective(s) of the guideline is (are) specifically describedThe overall objective(s) of the guideline is (are) specifically described11. Scope and purposeNo change2The clinical question(s) covered by the guideline is (are) specifically describedThe [health]{.ul} question(s) covered by the guideline is (are) specifically described2Change in underline part3The patients to whom the guideline is meant to apply are specifically describedThe [population (patients, public, etc.)]{.ul} to whom the guideline is meant to apply is specifically described3Change in underline part2. Stakeholder involvement4The guideline development group includes individuals from all the relevant professional groupsThe guideline development group includes individuals from all the relevant professional groups42. Stakeholder involvementNo change5The patients' views and preferences have been soughtThe views and preferences of [the target population (patients, public, etc.)]{.ul} have been sought5Change in underline part6The target users of the guideline are clearly defined. NoThe target users of the guideline are clearly defined. No6No change7The guideline has been piloted among end usersDelete item. Incorporated into user guide description of item 193. Rigour of development8Systematic methods were used to search for evidenceSystematic methods were used to search for evidence73. Rigour of developmentNo change, renumber to 79The criteria for selecting the evidence are clearly describedThe criteria for selecting the evidence are clearly described8No change, renumber to 8The strengths and limitations of the body of evidence are clearly described9New item10The methods for formulating the recommendations are clearly describedThe methods for formulating the recommendations are clearly described10No change11The health benefits, side effects, and risks have been considered in formulating the recommendationsThe health benefits, side effects, and risks have been considered in formulating the recommendations11No change12There is an explicit link between the recommendations and the supporting evidenceThere is an explicit link between the recommendations and the supporting evidence12No change13The guideline has been externally reviewed by experts prior to its publicationThe guideline has been externally reviewed by experts prior to its publication13No change14A procedure for updating the guideline is providedA procedure for updating the guideline is provided14No change4. Clarity of presentation15The recommendations are specific and unambiguousThe recommendations are specific and unambiguous154. Clarity of presentationNo change16The different options for management of the condition are clearly presentedThe different options for management of the condition [or health issue]{.ul} are clearly presented16Change in underline part17Key recommendations are easily identifiableKey recommendations are easily identifiable17No change18The guideline is supported with tools for applicationThe guideline [describes facilitators and barriers to its]{.ul} application195. ApplicabilityChange in underline part, renumber to 19, change in domain from \#4 clarity of presentation to \#5 applicability5. Applicability19The potential organizational barriers in applying the recommendations have been discussed[The guideline provides advice and/or tools on how the recommendations can be put into practice]{.ul}18Change in underline part, renumber to 18.20The potential cost implications of applying the recommendations have been consideredThe potential [resource]{.ul} implications of applying the recommendations have been considered20Change in underline part21The guideline presents key review criteria for monitoring and/ or audit purposesThe guideline presents [monitoring and/ or auditing criteria]{.ul}21Change in underline part6. Editorial independence22The guideline is editorially independent from the funding body[The views of the funding body have not influenced the content of the guideline]{.ul}226. Editorial independenceChange in underline part23Conflicts of interest of guideline development members have been recorded[Competing]{.ul} interests of guideline development group members have been recorded [and addressed]{.ul}23Change in underline partOverall guideline assessmentRate the overall quality of this guideline1Overall guideline assessmentNew item1I would recommend this guideline for useI would recommend this guideline for use2Renumber to 2

As there was no item in AGREE I that corresponded with the new overall guideline assessment item in AGREE II, we attempted to calculate this value using two approaches. First, we calculated the average of the standardized score using results of the six AGREE I domains. Second, we calculated the standardized score using the results of the 23 AGREE I items. We examined the correlation between "Overall Guideline Assessment" in the AGREE II and the results of the two approaches described above.

We used t-tests to compare standardized scores, and calculated correlation coefficients for each AGREE I and AGREE II item and domain. p values \< 0.05 were indicated statistical significance. All analyses were performed using SPSS, version 20.0 (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.).

Results {#Sec4}
-------

The results of the AGREE I and AGREE II evaluations are shown in Fig. [1](#Fig1){ref-type="fig"}. Correlation coefficients are shown in Table [2](#Tab2){ref-type="table"}. High correlations were observed in all domains: scope and purpose = 0.758; stakeholder involvement = 0.756; rigor of development = 0.992; clarity of presentation = 0.865; applicability = 0.938; and editorial independence = 0.938. The correlation coefficients of each item ranged from 0.708 to 0.982.Fig. 1Evaluation of clinical practice guidelines, published between 2011 and 2012, using the AGREE I and AGREE II (n = 68). t test; \*p \< 0.05, \*\*p \< 0.01 Table 2Correlation between the AGREE I and AGREE II domainsAGREE IAGREE II123456TotalAverage123456TotalOverall guideline assessmentAGREE I 1. Scope and purpose1.0000.1440.366\*\*0.162− 0.0770.1720.371\*\*0.332\*\*0.758\*\*0.1970.365\*\*0.100− 0.0510.1560.368\*\*0.328\*\* 2. Stakeholder involvement1.0000.1210.352\*\*0.106− 0.0590.302\*0.308\*0.1130.708\*\*0.1070.2290.248\*− 0.0790.2330.114 3. Rigour of development1.0000.428\*\*0.243\*0.491\*\*0.938\*\*0.849\*\*0.260\*0.0130.982\*\*0.483\*\*0.263\*0.491\*\*0.943\*\*0.736\*\* 4. Clarity of presentation1.0000.1220.0690.524\*\*0.502\*\*0.243\*0.337\*\*0.397\*\*0.702\*\*0.333\*\*0.1060.497\*\*0.339\*\* 5. Applicability1.0000.1460.423\*\*0.505\*\*− 0.0420.0070.1710.1060.919\*\*0.1410.361\*\*0.011 6. Editorial independence1.0000.561\*\*0.647\*\*− 0.0080.1670.484\*\*0.0790.1810.971\*\*0.575\*\*0.464\*\* Total1.0000.968\*\*0.268\*0.278\*0.905\*\*0.524\*\*0.473\*\*0.561\*\*0.978\*\*0.685\*\* Average1.0000.2110.302\*0.810\*\*0.468\*\*0.552\*\*0.646\*\*0.937\*\*0.628\*\*AGREE II 1. Scope and purpose1.0000.1740.276\*0.251\*− 0.0040.0010.303\*0.183 2. Stakeholder involvement1.0000.1610.289\*\*0.1290.1590.316\*\*0.247\* 3. Rigour of development1.0000.501\*\*0.1820.479\*\*0.938\*\*0.771\*\* 4. Clarity of presentation1.0000.1550.0920.570\*\*0.492\*\* 5. Applicability1.0000.1890.403\*\*0.033 6. Editorial independence1.0000.575\*\*0.445\*\* Total1.0000.746\*\* Overall guideline assessment1.000\* p \< 0.05, \*\* p \< 0.01

Correlation coefficients for the 22 items ranged from 0.694 to 0.995; 16 items had a correlation coefficient of 0.9 or more, three items were 0.8--0.9, and three items were 0.6--0.8. A high overall correlation was observed for all items (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

The newly-introduced overall assessment item "Overall Guideline Assessment" (AGREE II) should be assessed based on AGREE I data. The six AGREE I domains had a correlation coefficient of 0.628, when 23 items were used it was 0.685, suggesting a higher related value could be gained using the latter (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec5}
----------

Since its publication in 2003, the high popularity of the AGREE instrument has produced a large amount of evaluation data. With the revision of the AGREE instrument, the relationship between data obtained from AGREE I and AGREE II, and data conversion from the AGREE I to the AGREE II are high research agenda priorities for investigating time trend analyses of CPG quality.

For the 68 CPGs issued in 2011--2012, our results demonstrated that AGREE I and AGREE II were highly correlated at both the domain and item levels, and the newly introduced overall rating item "Overall Guideline Assessment" could be calculated more precisely using the 23 AGREE I items, rather than domain-level data.

Increasing attention is being directed to safety and quality issues, and CPGs based on EBM are a representative method for standardizing and improving the quality and safety of healthcare procedures. The AGREE instrument is widely used to measure CPG quality. Our results suggest that the AGREE instrument can still be used as a measurement tool, which exhibits high consistency, although it has now been revised (AGREE II). It enables long-term, comprehensive CPG evaluation. The Japanese government has promoted CPG preparation since 1996. Our study may help evaluate the underlying policy guidelines.

Conclusion {#Sec6}
----------

Data obtained from AGREE I can be transferred to the AGREE II, and the data for "Overall Guideline Assessment" can be calculated with high reliability using a standardized score of the 23 items.

Limitations {#Sec7}
===========

Our evaluation team did not include any researchers or clinicians. However, the expert librarians had extensive knowledge about CPG preparation and had experience evaluating CPGs using the AGREE measure.

Additional file {#Sec8}
===============

**Additional file 1: Table S1.** Correlation between the AGREE I and AGREE II items. \*p \< 0.05, \*\*p \< 0.01.
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